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1 |  INTRODUCTION
Branched-chain amino acids (BCAA: leucine, isoleucine, 
and valine) alone or in combination with resistance exercise 
have anabolic effects on skeletal muscle. Consistent with this, 
BCAAs, and in particular leucine, can induce signaling that 
promotes muscle protein synthesis via the mammalian/mech-
anistic target of rapamycin complex 1 (mTORC1) (Anthony, 
Anthony, & Layman, 1999; Matsumoto et al., 2007), inhibit 
protein degradation via the ubiquitin-proteasome system 
(Herningtyas et al., 2008), improve mitochondrial metabo-
lism (D’Antona et al., 2010), and improve glucose transport 
and insulin signaling in some (Kleinert et al., 2011; Liu et al., 
2014; Nishitani et al., 2002) though not all (Moghei, Tavajohi-
Fini, Beatty, & Adegoke, 2016) studies. Interestingly, many 
of the anabolic features of BCAA can be mimicked by me-
tabolites of these amino acids. For example, the ketoacid of 
leucine, α-ketoisocaproic acid (KIC), can activate mTORC1 
and stimulate muscle protein synthesis (Escobar et al., 2010; 
Lynch et al., 2003; Moghei et al., 2016; Xu, Kwon, Cruz, 
Marshall, & McDaniel, 2001).
The first step in the catabolism of BCAA is the reversible 
conversion of these amino acids to their corresponding α-ke-
toacids (α-ketoisocaproate (KIC), α-keto-β-methylvalerate 
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Abstract
Much is known about the positive effects of branched-chain amino acids (BCAA) in 
regulating muscle protein metabolism. Comparatively much less is known about the 
effects of these amino acids and their metabolites in regulating myotube formation. 
Using cultured myoblasts, we showed that although leucine is required for myotube 
formation, this requirement is easily met by α-ketoisocaproic acid, the ketoacid of 
leucine. We then demonstrated increases in the expression of the first two enzymes 
in the catabolism of the three BCAA, branched-chain amino transferase (BCAT2) 
and branched-chain α-ketoacid dehydrogenase (BCKD), with ~3× increase in BCKD 
protein expression (p < .05) during differentiation. Furthermore, depletion of BCAT2 
abolished myoblast differentiation, as indicated by reduction in the levels of myosin 
heavy chain-1, troponin and myogenin. Supplementation of incubation medium with 
branched-chain α-ketoacids or related metabolites derivable from BCAT2 functions 
did not rescue the defects. However, co-depletion of BCKD kinase partially rescued 
the defects. Collectively, our data indicate a requirement for BCAA catabolism dur-
ing myotube formation and that this requirement for BCAT2 likely goes beyond the 
need for this enzyme to generate the α-ketoacids of the BCAA.
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(KMV), and α-ketoisovalerate (KIV), respectively from leu-
cine, isoleucine and valine). Because α-ketoglutarate is the 
usual amino group acceptor in the transamination reactions of 
the BCAA, glutamate is also produced. In skeletal muscle, the 
formation of the ketoacids from the three BCAA is catalyzed 
by a single enzyme, the mitochondrial branched-chain ami-
notransferase 2 (BCAT2 or BCATm). The ketoacids can then 
be irreversibly oxidatively decarboxylated to their acyl-CoA 
derivatives (isovaleryl-CoA, 2-methylbutryl-CoA and isobu-
tyryl-CoA, respectively from KIC, KMV and KIV) by the 
branched-chain ketoacid dehydrogenase complex (BCKD). 
The resulting acyl-CoA derivatives can either be oxidized 
to yield ATP, CO2 and H2O, or enter alternative pathways. 
One of such pathways is the utilization of leucine-derived 
β-hydroxyl- β-methylglutaryl-CoA (HMG-CoA) for de novo 
cholesterol synthesis, an essential component in membrane 
biogenesis (Berg, Tymoczko, & Stryer, 2002). Unlike the me-
tabolism of the other BCAA, KIC can also be used to make 
β-hydroxy-β-methylbutyrate (HMB), a compound with pro-
tein anabolic effect in skeletal muscle (Girón et al., 2016).
Alterations in BCAA metabolism and metabolites affect 
whole body and skeletal muscle metabolism. For example, 
BCAT2 knock out mice have increased body weight, aug-
mented protein turnover and whole body insulin sensitivity 
but without an effect on skeletal muscle weight (She et al., 
2007). However, these animals, which have increased circu-
lating levels of BCAA but lower levels of the corresponding 
ketoacids and of glutamine, display impaired exercise ca-
pacity (She et al., 2010). Defects in BCKD activity, such as 
are seen in individuals with maple syrup urine disease, are 
associated with profound muscle and movement abnormal-
ities (Carecchio et al., 2011; Ferrière, Castro, & Rodriguez, 
1984; Friedrich, Lambert, Masino, & Downes, 2012; Jouvet, 
Kozma, & Mehmet, 2000; Jouvet et al., 1998). Finally, mice 
with muscle specific deletion of BCKD kinase (BDK, the 
enzyme that catalyzes the inhibitory phosphorylation of the 
E1α subunit of BCKD), which would lead to elevated BCKD 
activity, have exaggerated muscle catabolic response to pro-
tein deficiency (Ishikawa et al., 2017). These studies under-
line the significance of appropriate regulation of muscle and 
whole body BCAA catabolism in organismic metabolism and 
response to stressors.
Although the significance of BCAA in muscle growth and 
metabolism is incontrovertible, comparatively much less is 
known on the roles of these amino acids and their metabolites 
during muscle cell differentiation. Muscle cell differentiation 
is a vital process in converting mono-nucleated proliferating 
myoblasts to terminally differentiated, multi-nucleated myo-
tubes, the latter being the building blocks for forming new 
myofibers or repairing existing ones. When myotubes are 
formed, there is a change in the proteome such that there is an 
abundance of myofibrillar proteins, including myosin heavy 
chain, troponin, and tropomyosin. Since these new proteins 
need to be synthesized de novo, and given the significance 
of BCAA in regulating protein turnover, it is reasonable to 
envisage a role for these amino acids during differentiation. 
Moreover, there is a requirement for mTORC1 activation 
during differentiation (Erbay & Chen, 2001). BCAA might 
facilitate such an activation. Muscle cells can use leucine as 
a source of cholesterol (Miettinen & Penttilä, 1968), which 
potentially can be used in making myotube membranes during 
differentiation. Leucine can also serve as a fuel for oxidative 
metabolism (Bowtell, Marwood, Bruce, Constantin-Teodosiu, 
& Greenhaff, 2007) during differentiation, a process that is 
associated with increased mitochondrial content and oxidative 
metabolism (Malinska, Kudin, Bejtka, & Kunz, 2012). Along 
this line, myoblasts cultured in leucine-free medium do not 
differentiate well, a defect that is associated with abnormal 
regulation of myogenic regulatory factors (MRFs) myf5 and 
myoD (Averous, Gabillard, Seiliez, & Dardevet, 2012; Dai 
et al., 2015). In addition, HMB positively regulates the dif-
ferentiation of human and chicken skeletal muscle myoblasts 
(Kornasio et al., 2009). These studies suggest a role for BCAA 
and their metabolites in regulating muscle cell differentiation.
Here, we first examined the effects of leucine on myo-
blast differentiation. Our data revealed that while leucine is 
required for differentiation of L6 myoblasts, this requirement 
can be met by KIC supplementation. In addition to reporting 
an increase in the levels of the first two enzymes in BCAA 
catabolic pathway during differentiation, we demonstrated a 
requirement for BCAT2 for optimal myotube formation and 
showed that this requirement likely goes beyond its ability to 
produce the α-ketoacids from the BCAA.
2 |  MATERIALS AND METHODS
2.1 | Reagents
Fetal Bovine Serum (FBS), Horse Serum (HS), Lipofectamine 
RNAiMAX, OptiMEM, and antibiotic/antimycotic rea-
gents were purchased from Life Technologies. Pierce BCA 
Protein Assay Kit and RNA isolation kits were obtained from 
Thermo Fisher; leucine-free medium (RPMI 1640) from US 
Biologicals; alpha ketoisocaproic acid (KIC), phosphatase 
and protease inhibitor cocktails, scramble, BDK and BCAT2 
siRNA oligonucleotides were purchased from Sigma-Aldrich. 
α-Modification of Eagle's Medium (AMEM) and Phosphate 
Buffered Saline (PBS) were obtained from Wisent.
2.2 | Antibodies
Antibodies to branched-chain α-ketoacid-dehydrogenase E1 
α-polypeptide (BCKDE1α), BCAT2 and to γ-tubulin were 
purchased from Sigma–Aldrich. Antibodies to phosphorylated 
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ribosomal protein S6 (S235/236), phosphorylated AKT 
(S473), caspase 3, caspase 7, poly (ADP-ribose) polymerase 
(PARP), GAPDH, and HRP-conjugated rabbit and mouse IgG 
were purchased from Cell Signaling Technology. Antibodies 
to troponin, myogenin and myosin heavy chain-1 (MHC-1) 
were obtained from Developmental Studies Hybridoma Bank.
2.3 | Cell culture and differentiation
L6 rat myoblasts were obtained from the American Type 
Culture Collection. Cells (5.0 × 105) were seeded in 10-cm 
plates in growth medium (GM) (AMEM supplemented 
with 10% fetal bovine serum and 1% antibiotic-antimycotic 
agents) and incubated at 37°C and 5% CO2. To initiate differ-
entiation, cells were first grown to ~90% confluency in 6-well 
plates and then shifted into differentiation medium (DM) 
consisting of AMEM, 1% antibiotic-antimycotic agents, and 
2% horse serum. DM was replaced every 24 hr.
2.4 | Leucine deprivation and KIC rescue 
experiments
To examine how differentiation was affected by depriving 
myoblasts of leucine, 1.5 × 105 cells were cultured in 6-well 
plates. Once cells reached ~90% confluency, the medium was 
changed to the differentiation medium consisting of RPMI 
1640, 2% horse serum, and 1% antibiotic-antimycotic agents. 
This RPMI medium was used because it lacks l-leucine, l-glu-
tamine, and sodium bicarbonate). l-glutamine and sodium bi-
carbonate were re-added to all RPMI media at concentrations 
to mimic their levels in common growth media. RPMI differ-
entiation media was changed every 24 hr. To test if the leucine 
metabolite KIC can rescue leucine-deprived cells, cells were 
differentiated in a medium that was leucine-free, or leucine-
free but supplemented with 200 µM KIC. The supplemented 
differentiation medium was changed every 24 hr. On D0 to 
D5 of differentiation, batches of cells were washed with cold 
PBS and harvested with 100 µl lysis buffer (1 mM EDTA, 2% 
sodium dodecyl sulfate (SDS), 25 mM Tris, 1 mM DTT, sup-
plemented (10 µl/ml) with each of protease and phosphatase 
inhibitor cocktails. Samples were stored at −20°C.
2.5 | Effect of BCAT2 depletion on myoblast 
differentiation
We utilized RNAi to deplete myoblasts of BCAT2, using lipo-
fectamine RNAiMAX (Life Technologies). Briefly, 2.5 × 105 
cells were seeded in 6-well plates along with either scramble 
(control, Sigma #SIC001) or BCAT2 siRNA oligonucleo-
tides (sense 5′-CUAUGUGCGGCCGGUGCUU, anti-sense 
5′-AAGCACCGGCCGCACAUAG) as described previously 
(Maeda, Abdullahi, Beatty, Dhanani, & Adegoke, 2017; Moghei 
et al., 2016). After 48 hr, cells were either harvested (D0 of dif-
ferentiation) or washed twice with PBS and shifted into regu-
lar (complete) DM. At D1–D5, samples were harvested with 
100 μl lysis buffer, and stored at −20°C for later analysis.
2.6 | Rescuing differentiation defects 
in BCAT2-depleted cells by increasing 
cell number
Because BCAT2 depletion reduced the number of viable cells 
(see Results section), we wondered if adding more cells could 
rescue the differentiation defects seen in BCAT2-depleted 
myoblasts. To address this, 24  hr following transfection of 
cells with control or BCAT2 siRNA oligonucleotides in 6-well 
plates, we trypsinized three wells of the BCAT2 siRNA-treated 
cells and combined them into one new well. Similarly, for the 
control siRNA treated cells, we trypsizined one well and sim-
ply moved the cells into one new well. We only used one well 
for control cells because cell death was minimal in control cells 
compared to BCAT2 depleted cells, but those cells were trypsi-
nized nevertheless to ensure identical handling between the two 
groups. Once the cells from both treatments were placed into 
new wells, they were allowed to grow in regular (complete) 
GM for another 24 hr. Cells were then shifted into regular DM 
and their ability to differentiate was examined.
2.7 | Branched-chain ketoacid (BCKA) 
rescue experiment in BCAT2 depleted cells
Because a primary function of BCAT2 is to generate the 
branched-chain α-ketoacids, we examined whether adding these 
ketoacids (KIC, KMV, and KIV) would rescue differentiation 
defects in BCAT2-depleted cells. L6 myoblasts (2.5  ×  105) 
cells were transfected with control or BCAT2 siRNA transfec-
tion mix. Twenty-four hours after transfection, 1 ml of regular 
GM was added to all wells. In BCAT2 siRNA-treated wells, 
KIC, KIV, and KMV were also added to a final concentration 
of 200 μM for each of the ketoacids. After another 24 hr, the 
cells were shifted to regular DM, and again with or without 
added KIC, KIV, and KMV. DM was changed every subse-
quent 24 hr, with the stated ketoacids added as indicated above.
2.8 | Effects of BCAT2 and BCKD kinase 
(BDK) co-depletion on myoblast differentiation
To study the effect of BDK depletion on the differentiation of 
myoblasts with attenuated BCAT2 level, myoblasts were trans-
fected with BCAT2 siRNA oligonucleotides as before, but with 
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or without co-transfection with BDK siRNA oligonucleotides 
(sense 5′-CUAUGCAUGGCUUUGGCUU, anti-sense 5′- 
AAGCCAAAGCCAUGCAUAG). Forty-eight h later, myo-
blasts were harvested or cultured in regular DM. Cells were 
harvested at different times during differentiation and processed.
2.9 | Western blotting
After determining protein concentrations in cell lysate, 
samples were run on either 10% or 15% SDS-page gels and 
transferred to PVDF membranes. Western blot analysis was 
done as described previously (Maeda et al., 2017; Moghei 
et al., 2016). MHC-1, BCKDE1α, and troponin were blotted 
for using the membranes from 10% gels, whereas, BCAT2, 
phosphorylated (ph) S6, caspase-3, and myogenin were blot-
ted for using the membranes from 15% gels.
2.10 | mRNA analysis
Cells were differentiated as described above. RNA was iso-
lated from sample harvested D0 to D5 using an RNA isolation 
kit (Thermo-Fisher) and following manufacturer's instruc-
tions. RNA was stored at −80°C. cDNA was synthesized 
from RNA using a cDNA synthesis kit (Bio-Rad). Sybr-green 
chemistry based quantitative PCR (qPCR) was conducted 
using the Bio-Rad SsoAdvanced™ Universal SYBR® Green 
Supermix and analyzed using Bio-Rad CFX96™ machine 
(Maeda et al., 2017). The following primers were used: 
BCAT2 [Forward: 5′-TCCAGAACCTCACAGTGC-3′ 
Reverse: 5′-CCTGCTTGTCAAAGTCTG-3′], BCKDE1α 
[Forward: 5′-GGGCTTGGCTAGATTCA-3’ Reverse: 
5′-GGGGATCTTCACTGGGGT-3′], HPRT [Forward: 
5′-GCTTTCCTTGGTCAAGCAC-3′ Reverse: 
5′-TCCAACAAAGTCTGGCCTGA-3′]. We corrected for 
RNA quantity using the mRNA level of HPRT (hypoxan-
thine phosphoribosyltransferase 1).
2.11 | Other analyses
Intracellular BCAA concentrations in cell lysate were 
measured as described previously (Beckett et al., 1996; 
Jeganathan, Abdullahi, Zargar, Maeda, & Riddell, 2014). 
We measured cell viability by using the CCK-8 cell viability 
assay kit (Sigma #96992) and following the manufacturer's 
instructions. Cell viability is expressed relative to the cells 
cultured and differentiated in medium lacking siRNA rea-
gents or siRNA oligonucleotides.
2.12 | Statistical analysis
Two tailed non-paired t-test was used to assess the difference 
between two groups. One-way ANOVA with Tukey Kramer 
post-hoc test was conducted on experiments with more than two 
groups. Values are means ± SEM. Unless otherwise indicated, 
n = 3 independent experiments (biological replicates). Within 
each biological replicate, we assigned ≥wells per treatment. 
Statistical significant difference was determined as p < .05.
3 |  RESULTS
3.1 | Leucine essentiality for differentiation 
can be met by KIC
Whereas myoblasts differentiated in the medium that lacked 
the non-essential amino acid alanine, no differentiation was 
observed in cells grown in the absence of leucine, as indi-
cated by the absence of myotubes (Figure 1a) and expression 
of myofibrillar proteins, including MHC-1 and troponin and 
of myogenic regulatory factor myogenin (Figure 1b–e). The 
requirement for the essential amino acid leucine was fully 
met when its ketoacid, KIC, was provided. (Figure 1a–e). 
KIC also restored mTORC1/S6K1 signaling in cells lack-
ing leucine, as reflected in the abundance of phosphorylated 
S6 ribosomal protein (Figure 1f). Conclusively, these results 
demonstrate the BCAA leucine is essential to L6 myoblast 
differentiation and that in its absence, KIC rescues the ob-
served defects.
3.2 | Expression of BCAA catabolic enzymes 
BCAT2 and BCKD increase during L6 
differentiation
Because we observed that KIC, a metabolite of leucine 
catabolism, could recapitulate the functions of leucine 
F I G U R E  1  Leucine requirement during differentiation of myoblasts can be met by KIC. (a) L6 rat myoblasts were differentiated in either a 
differentiation medium (DM) with all amino acids (CTR), or DM lacking only l-alanine, DM lacking only l-leucine, or DM lacking only l-leucine 
but also supplemented with 200 µM KIC for a period of 5 days. Day 0 (D0) represents the moment immediately before shifting the cells into the 
differentiation medium while day 5 (D5) represents the moment after allowing the cells to differentiate for 5 days. (b–e) Cells were harvested 
on day 0 (D0) and day 5 (D5) and probed for myosin heavy chain-1 (MHC-1), troponin, and myogenin, which are markers of differentiation. 
(f) Phosphorylated ribosomal protein S6 (a marker of mTORC1 signaling). In c–f, data are mean ± SEM; n = 3 independent experiments (i.e., 
biological replicates). *significantly different compared to all other conditions in the D5 group (p < .05)
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during differentiation, we wondered how the enzymes that 
catabolize the BCAA were regulated during myoblast dif-
ferentiation. BCAT2 (the BCAT isoform found in skeletal 
muscle) was robustly expressed in myoblasts. Although the 
abundance of BCAT2 appeared highest on day 3 (D3) of 
differentiation, there was no statistically significant effect 
of differentiation on the abundance of this enzyme (Figure 
2a). Expression of the E1α subunit of BCKD showed a 
significant trend to increase on all days of differentiation, 
where D4 and D5 were significantly higher compared to 
D1 of differentiation (p < .05) (Figure 2b). At the mRNA 
level, we found no statistically significant changes in 
BCAT2 expression. However, BCKDE1α mRNA was sig-
nificantly higher on D2 of differentiation compared to D0, 
and thereafter declined (Figure 2c). The observed trends 
in BCAT2 and BCKD expression were not associated 
with any statistically significant change in intracellular 
levels of the BCAA over the 5-day differentiation period 
(Figure 2d).
3.3 | BCAT2 depletion prevents L6 myoblast 
differentiation
Our observation that KIC can meet the requirement 
for leucine and of increased expression of a criti-
cal subunit of BCKD during differentiation suggests a 
requirement for BCAT2 both for transamination of KIC 
back to leucine and to generate substrates for BCKD. 
Indeed, whereas cells transfected with scramble siRNA 
oligonucleotides (CTR siRNA) differentiated well, 
BCAT2 knockdown cells showed no visible myotubes 
(Figure 3a–c) and had markedly reduced levels of MHC 
(~20% of MHC in CTL siRNA group on D3) (Figure 
3b and d). In addition, those cells had no detectable 
levels of troponin and myogenin (Figure 3b, e, and f). 
Interestingly, in cells depleted of BCAT2, phosphoryl-
ation of S6 was significantly reduced at D2 (p  <  .05) 
and showed a trend to be reduced at D3 and D4 as well 
(Figure 3b and g). Clearly, these results suggest that 
BCAT2 serves an essential role in the differentiation of 
myoblasts to myotubes.
3.4 | Increasing cell confluency does not 
rescue differentiation defects in BCAT2-
depleted myoblasts
Upon BCAT2 transfection, we observed a marked reduc-
tion in cell number, especially on D1 and D2 (Figure 3a). 
By D4 and 5, cell number improved, likely as a result of a 
diminishing effect of RNAi on BCAT2 level (see Figure 
3b). Cell viability was also reduced in BCAT2-depeleted 
cells, especially on D2 of differentiation (Figure 4a). We 
F I G U R E  1  (Continued)
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therefore attempted to rescue the differentiation defects 
by increasing cell number at the time of shift into the DM 
(Figure 4b; please see Method section). As expected, aug-
menting cell number increased cell confluency at D0 and 
D1 of differentiation, as there were minimal empty spaces 
between cells in the BCAT2 siRNA treatment group (Figure 
4b and c compared to Figure 3a). In spite of this, however, 
BCAT2-depletedcells still showed an absence of differen-
tiation and exhibited a marked reduction in cell number at 
D3 of differentiation (Figure 4b), suggesting that the reason 
BCAT2 deficient myoblasts did not fuse and differentiate 
was not due to reduced number of adherent cells at the onset 
of differentiation.
3.5 | Branched-chain α-ketoacid 
supplementation does not rescue differentiation 
defects in BCAT2-depleted myoblasts
Since BCAT2 produces KIC, KMV, and KIV (the ketoacids 
of leucine, isoleucine, and valine, respectively), we wondered 
if supplementation of these ketoacids would rescue the dif-
ferentiation defects seen in BCAT-2 depleted cells. However, 
addition of these BCKAs to BCAT2 depleted cells resulted 
in no visible amelioration of myoblast fusion, cell death, and 
the expression of myofibrillar proteins, and of myogenin 
(Figure 5a–e). Hence, the reason BCAT2-depletion nega-
tively affects myoblast differentiation is likely due to another 
F I G U R E  2  Expression of 
BCAT2 and BCKD during myoblast 
differentiation. (a) BCAT2 (branched-chain 
aminotransferase-2) and (b) BCKDE1α 
(E1α subunit of branched-chain alpha-
ketoacid dehydrogenase) protein expression 
during differentiation of L6 myoblasts 
in regular DM. *significantly greater 
than day 1 (D1) (p < .05). (c) mRNA 
expression of BCAT2 and BCKDE1α 
during differentiation of L6 myoblasts. 
Data are mean ± SEM, n = 3 independent 
experiments. *significantly different from 
D5 (p < .05). (d) Intracellular BCAA 
concentration at each day of differentiation
a
c
d
b
8 of 15 |   DHANANI et Al.
F I G U R E  3  BCAT2 depletion impairs 
myotube formation. L6 rat myoblasts were 
transfected with control (CTR) or BCAT2 
siRNA oligonucleotides. Two days later, 
myoblasts were harvested or shifted into 
regular DM. Samples were harvested on D1-
D5 of differentiation. (a) Light microscope 
images of cell during differentiation. Cells 
were harvested and probed for BCAT2 (b 
and c) and for myogenic proteins MHC-1, 
troponin, and myogenin (b and d–f), and 
(g) Ribosomal protein S6 phosphorylation. 
Data are mean ± SEM; n = 3 independent 
experiments. *significant difference from 
corresponding scramble group (p < .05)
a
b
c
e f
g
d
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BCAT2-mediated function other than BCKA production. 
Furthermore, supplementation of differentiation medium 
with vitamin B6 (the co-enzyme of BCAT2), a-ketoglutarate, 
glutamic acid, and glutamine (substrates/products of BCAT2 
reaction) did not correct differentiation defects in BCAT2-
depletion defects (data not shown).
3.6 | BCAT2 depletion induces programmed 
cell death in myoblasts
To determine the mechanism by which BCAT2 deple-
tion affected cell number, we probed for caspase-3 protein, 
which when cleaved, induces programmed cell death via 
F I G U R E  4  Differentiation defect 
in BCAt2-depleted cells is not rescued by 
increasing cell confluency at the onset of 
differentiation. Cells were transfected with 
CTL or BCAT2 siRNA oligonucleotides as 
described in the legend to Figure 3. Twenty 
four h following transfection, we trypsinized 
3 wells of the BCAT2 siRNA-treated cells 
and combined them into one new well. 
Similarly, for the control siRNA treated 
cells, we trypsizined 1 well and simply 
moved the cells into 1 new well. Cells were 
allowed to grow in regular GM for another 
24 hr. They were then shifted into regular 
DM and their ability to differentiate was 
examined. (a) Cell viability was measured 
in cells transfected with two different 
BCAT2 siRNA oligonucleotides. Effects of 
increasing cell number (b) on differentiation 
(c) in BCAT2-depeleted cells. For a, data 
are mean ± SEM; *significant difference 
(p < .05) from BCAT2-siRNA; n = 3 
independent experiments
a
b
c
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F I G U R E  5  Supplementation with branched-chain ketoacids does not rescue differentiation defects in cells depleted of BCAT2. Myoblasts 
transfected with BCAT2 siRNA oligonucleotides as described in the legend to Figure 1 were cultured in a regular DM supplemented with a 
combination of 200 µM of α-ketoisocaproate (KIC), 200 µM α-ketomethylvalerate (KMV), and 200 µM α-ketoisovalerate (KIV). (a) Light 
microscope images of cells at time of shifting into DM (D0) and on day 1, (D1), 3 and 5 of differentiation. (b–e) Expression of myogenic proteins 
MHC-1, troponin, and myogenin. (f and g) Apoptosis marker caspase 3 expression. Data are mean ± SEM; *significant difference (p < .05) 
from BCAT2-siRNA within same day; n = 3 independent experiments. In (f and g), n = 2. CTR siRNA: cells transfected with scramble siRNA 
oligonucleotides; BCAT2i: cells transfected with BCAT2 siRNA oligonucleotides; BCATi + KIC/KMV/KIV: cells transfected with BCAT2 
siRNA oligonucleotides and cultured in a medium supplemented with the three α-ketoacids of the BCAA
a
b
c
f
d e
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apoptosis (Mukasa, Momoi, & Momoi, 1999). We observed 
that BCAT2 knockdown significantly increased the amount 
of cleaved caspase-3 at D1 of differentiation (p < .05) (Figure 
5f and g). Supplementing BCKAs to BCAT2-depleted myo-
blasts did not rescue levels of cleaved caspase-3, suggesting 
that increased apoptosis might be responsible for reduced cell 
number during differentiation in BCAT2-depleted cells.
3.7 | Concurrent knockdown of BDK 
rescues differentiation defects in BCAT2-
depleted myoblast
Interactions between BCAT2 and BCKD complex promote 
flux through the BCAA catabolic pathway (Islam et al., 
2007). We have shown that knockdown of branched-chain 
α-ketoacid dehydrogenase kinase (BDK), a kinase that phos-
phorylates and inactivates BCKD, increases BCKD activity 
and promotes myotube formation (Brendan Beatty and OAJ 
Adegoke, unpublished observations). Therefore, we exam-
ined whether increasing BCKD activity via BDK knockdown 
(Figure 6a) would rescue differentiation defects observed in 
BCAT2 knockdown cells. On D4 and 5, concurrent BDK 
knockdown partially restored MHC and myogenin levels in 
BCAT2-depleted cells, and the effect of BDK knockdown 
was significant on D5 (Figure 6b and c). Thus, concurrent 
BDK knockdown partially rescues differentiation defects 
seen in myoblasts with reduced levels of BCAT2.
4 |  DISCUSSION
We have demonstrated a requirement for appropriate regula-
tion of BCAA catabolism for optimal muscle cell differentia-
tion. While a requirement for leucine during differentiation 
might be expected since leucine is an essential amino acid, 
we have demonstrated that this requirement is easily met 
by provision of KIC, the transamination product of leucine. 
Significantly, even in the presence of sufficient amount of 
branched-chain amino acids and their ketoacids, we demon-
strated a specific requirement for BCAT2 during the differ-
entiation of muscle cells. The impairment in differentiation in 
BCAT2-deficient cells could not be rescued with the provi-
sion of the ketoacids of BCAA or with related products of 
BCAA catabolism but was partially rescued by co-depletion 
of BDK, suggesting a role for BCKD in regulating the func-
tions of BCAT2 and therefore muscle cell differentiation.
Evidence to support a role for BCAA in skeletal muscle 
anabolism, especially with regard to stimulation of protein 
synthesis and suppression of muscle proteolysis, is incontro-
vertible. However, skeletal muscle anabolism can occur not 
only by an increase in protein mass of individual fibers, but 
also through an increase in myotube number, some of which 
can fuse with existing myofibers or form new fibers (Yin, 
Price, & Rudnicki, 2013). Given the myriad of changes that 
takes place during the differentiation of myoblast to myo-
tubes, for example the formation of myofibrillar proteins, it 
is remarkable that not much is known about nutritional reg-
ulation of this process, more so because nutrients are well 
known to regulate protein synthesis. Components of the nu-
trient sensitive pro-anabolic mTORC1 signaling, including 
RagA, RagB, and vps34 have all been implicated in myoblast 
to myotube differentiation (Yoon & Chen, 2013).The fact that 
leucine requirement for differentiation is met by provision of 
KIC, the ketoacid of leucine, is consistent with other reports 
showing that many of the anabolic effects of leucine are du-
plicated by KIC (Escobar et al., 2010; Lynch et al., 2003). An 
increase in the abundance of BCAA catabolic enzymes, es-
pecially in the protein and mRNA abundance of the catalytic 
E1α subunit of BCKD during differentiation, and an inability 
of cells depleted of BCAT2 to differentiate strongly suggest 
that increased catabolism of these amino acids is vital for 
differentiation. However, this happens without any apparent 
change in intracellular BCAA concentrations, suggesting 
that during differentiation, the transport of these amino acids 
likely also increases.
Cell-to-cell contact is vital for cell fusion and myotube 
formation (Abmayr & Pavlath, 2012). Although BCAT2 de-
pletion led to decreases in cell number, the fact that impaired 
differentiation was still observed when cell confluency was 
increased suggests that decreased cell number on D0 per 
see was not the cause of impaired differentiation. Rather, 
in confluent cells, BCAT2 depletion appears to lead to the 
F I G U R E  5  (Continued)
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accumulation of cells that although were in contact with other 
cells, were simply differentiation incompetent, resulting in 
increased apoptosis. The mechanisms by which BCAT2 de-
pletion led to decreased cell number or increased apoptosis 
is not clear. However, BCAT2 mediates decreased cell pro-
liferation observed in pancreatic adenocarcinoma cell lack-
ing mitochondrial malic enzymes 2 and 3 via its supply of 
glutamine for nucleotide synthesis (Dey et al., 2017). While 
we cannot rule out a role for BCAT2 in regulating myoblast 
proliferation, our data suggest a role for the enzyme in regu-
lating apoptosis in postmitotic myocytes.
The fact that provision of the ketoacids of BCAA did 
not rescue differentiation defects on BCAT2 depleted cells 
suggest that products other than the BCKA that are linked 
to BCAT2 might be limiting for myotube formation in cells 
depleted of BCAT2. These would include α-ketoglutarate, 
alanine, glutamic acid (the usual transamination substrate/
product of BCAT2 action) and glutamine (from glutamate 
amidation). BCAT2 knockout mice have up to 80% decline 
in muscle concentration of alanine, glutamate, and glutamine 
(She et al., 2010). A lack of myoblast differentiation is likely 
not due to alanine deficiency as we showed that alanine depri-
vation did not affect differentiation (Figure 1). Glutamine is 
metabolized in skeletal muscle and is linked to mTORC1 
activation (Jewell et al., 2015). However, the differentiation 
medium in which the cells were cultured contained 75 mg/L 
and 292  mg/L of l-glutamic acid and l-glutamine, respec-
tively. Further supplementation with glutamine and glutamic 
acid or addition of α-ketoglutarate did not rescue differenti-
ation defects. This suggests that other metabolites, for exam-
ple downstream of the BCKA, might be limiting. It is also 
possible that BCAT2 interacts with/regulates the functions 
of other proteins that might be critical for differentiation. 
Physical interactions between BCAT2 and BCKD promote 
flux through BCAA catabolic pathway (Islam et al., 2007). A 
lack of BCAT2 and the subsequent reduction in flow of sub-
strates for downstream metabolism might affect the produc-
tion of substrates and reduced equivalents (NADH, FADH2) 
that may regulate myotube formation. This is consistent with 
our data showing partial correction of differentiation defects 
in myoblasts with simultaneous knock down of BCAT2 and 
BDK. These results suggest a role for BCKD in facilitating 
the functions of BCAT2 during myoblast differentiation.
We showed that myoblasts depleted of BCAT2 have re-
duced mTORC1 signaling. There is evidence that mTORC1 
regulates muscle cell differentiation (Coolican, Samuel, 
Ewton, McWade, & Florini, 1997; Erbay & Chen, 2001). 
Because of a need for myofibrillar protein synthesis and the 
fact that mTORC1 is regulator of protein synthesis, further 
studies will be needed to clarify whether there is a link be-
tween reduced mTORC1 signaling and impaired cell differ-
entiation in myoblasts with reduced BCAT2 levels.
A weakness of this work is that experiments were car-
ried out in an immortalized cell line. Although it would be 
necessary to confirm whether these observations can be re-
produced in primary muscle cells, many of the significant 
discoveries on the molecular regulation of muscle mass and 
metabolism were initially identified in vitro models like ours. 
Therefore, it is likely that our data reflect what is going on in 
primary muscle cells. Other measures of cell differentiation, 
including fusion index, could also be used to assess treatment 
effects on this process. However, changes in the expression 
of myofibrillar proteins occur in parallel with fusion index 
and are routinely used to determine treatment effects on dif-
ferentiation (Millay et al., 2013; Wiles et al., 2015). Finally, 
our work demonstrating a requirement for leucine during 
differentiation used leucine-free medium, which would 
rarely occur in vivo. It would be interesting to see whether 
graded levels of leucine have differential effects of myoblast 
differentiation.
In conclusion, we showed a requirement for BCAT2 
during differentiation of muscle cells from myoblasts to 
myotubes. We demonstrated that impairment in differenti-
ation in BCAT2-depleted cells could not be corrected by 
provision of BCAA-derived α-ketoacids and other proximal 
products of the reaction catalyzed by enzyme but that these 
defects could be partially rescued by co-depletion of BDK. 
Because formation of new muscle fibers is needed for mus-
cle repair (Karalaki, Fili, Philippou, & Koutsilieris, 2009), if 
these data are reproduced in primary myocytes, our findings 
suggest that interventions that modulate BCAA catabolism 
might hold promise for treatment of muscle regeneration 
after damage due to, for example, trauma. Interestingly, 
impaired BCAA catabolism is seen in insulin resistance 
(Newgard et al., 2009; Wijekoon, Skinner, Brosnan, & 
Brosnan, 2004) and related metabolic diseases such as type 
2 diabetes (Kuzuya et al., 2008; Lotta et al., 2016) and car-
diovascular disease (Uddin et al., 2019), all of which are 
associated with some degree of muscle wasting (Kim et al., 
2014; Park et al., 2009; Tajiri, Kato, Nakayama, & Yamada, 
2010; Wang, Hu, Hu, Du, & Mitch, 2006). This raises the 
possibility that correcting the impairments in BCAA metab-
olism may be beneficial in treating associated sequelae seen 
in such diseases.
F I G U R E  6  Co-transfection of BCKD kinase (BDK) siRNA oligonucleotides ameliorates differentiation defects in BCAT2 depleted cells. 
L6 myoblasts were transfected with BCAT2 siRNA, with or without co-transfection with BDK siRNA oligonucleotides. Two days later, myoblasts 
were harvested or shifted into regular DM. Samples were harvested on D3-D5 of differentiation. (a) Western blot images for BCAT2 and BDK. 
(b–c) protein abundance of MHC-1 and myogenin. Data are mean ± SEM; n = 3 independent experiments; *significant difference in the indicated 
pair-wise comparisons (p < .05)
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